Please assess the completion status of the following clinical trial:

Trial Title: A Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Biologic Therapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Confirmed diagnosis of CD for at least 3 months prior to Baseline.~* Confirmed diagnosis of moderate to severe CD as assessed by stool frequency (SF), abdominal pain (AP) score.~* Evidence of mucosal inflammation based on the Simplified Endoscopic Score for Crohn's disease (SES-CD) on an endoscopy confirmed by a central reader.~* Demonstrated an inadequate response or intolerance to any biologic therapy for infliximab, adalimumab, certolizumab pegol, vedolizumab, and ustekinumab.~* If female, participant must meet the contraception recommendations.~Exclusion Criteria:~* Participant with a current diagnosis of ulcerative colitis or indeterminate colitis.~* Participant not on stable doses of CD related antibiotics, oral aminosalicylates, corticosteroids or methotrexate (MTX).~* Participant with the following ongoing known complications of CD: abscess (abdominal or peri-anal), symptomatic bowel strictures, fulminant colitis, toxic megacolon, or any other manifestation that might require surgery while enrolled in the study.~* Participant with ostomy or ileoanal pouch.~* Participant diagnosed with conditions that could interfere with drug absorption including but not limited to short gut or short bowel syndrome.~* Screening laboratory and other protocol pre-specified analyses show abnormal results.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Part 1 (Double-blind): Placebo (Type: PLACEBO_COMPARATOR): Participants received upadacitinib matching placebo tablets, orally, once daily (QD) for 12 weeks during the Double-blind (DB) Induction Period.
- Part 1 (Double-blind): Upadacitinib 45 mg (Type: EXPERIMENTAL): Participants received upadacitinib 45 mg tablets, orally, QD for 12 weeks during the DB Induction Period.
- Part 2 (Open-label): Upadacitinib 45 mg (Type: EXPERIMENTAL): Participants received upadacitinib 45 mg tablets, orally, QD for 12 weeks during the Open-label (OL) Induction Period.
- Part 3 (Extended Treatment DB): Upadacitinib 45 mg From Part 1 DB Placebo (Type: EXPERIMENTAL): Participants received upadacitinib 45 mg tablets, orally, QD for 12 weeks (until Week 24) during the Extended Treatment (ET) Period. Participants who received placebo in Part 1 and did not achieve clinical response at Week 12 were included in this group.
- Part 3 (Extended Treatment DB): Upadacitinib 30 mg From Part 1 DB Upadacitinib 45 mg (Type: EXPERIMENTAL): Participants received upadacitinib 30 mg tablets, orally, QD for 12 weeks (until Week 24) during the ET Period. Participants who received DB upadacitinib 45 mg in Part 1 and did not achieve clinical response at Week 12 were included in this group.
- Part 3 (Extended Treatment OL): Upadacitinib 30 mg From Part 2 OL Upadacitinib 45 mg (Type: EXPERIMENTAL): Participants received upadacitinib 30 mg tablets, orally, QD for 12 weeks (until Week 24) during the ET Period. Participants who received OL upadacitinib 45 mg during Part 2 and did not achieve clinical response at Week 12 were included in this group.

Based on this trial design, predict the completion outcome and termination type (if applicable).